J. Desager

发表

Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats.

C. Sempoux, I. Leclercq, Y. Horsmans, 2003, Journal of hepatology.

Dietary restriction of energy and sugar results in a reduction in human cytochrome P450 2E1 activity

I. Leclercq, S. Pauwels, Y. Horsmans, 1999, British Journal of Nutrition.

Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor).

Y. Horsmans, J. Desager, C. Harvengt, 1990, Pharmacology & toxicology.

High 6-Thioguanine Nucleotide Levels and Low Thiopurine Methyltransferase Activity in Patients With Lupus Erythematosus Treated With Azathioprine

F. Houssiau, Y. Horsmans, J. Desager, 2001, American journal of therapeutics.

Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine.

Y. Horsmans, J. Desager, G. Decaux, 2000, The Journal of laboratory and clinical medicine.

Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic

P. Hermann, J. Desager, C. Harvengt, 1988, Psychopharmacology.

Colestipol in familial type II hyperlipoproteinemia: A three‐year trial

J. Desager, C. Harvengt, 1976, Clinical pharmacology and therapeutics.

Hypoleptinemia in patients with anorexia nervosa: loss of circadian rhythm and unresponsiveness to short-term refeeding.

J. Balligand, S. Brichard, J. Desager, 1998, European journal of endocrinology.

Rosuvastatin Decreases Caveolin-1 and Improves Nitric Oxide–Dependent Heart Rate and Blood Pressure Variability in Apolipoprotein E−/− Mice In Vivo

J. Balligand, O. Feron, C. Dessy, 2003, Circulation.

Pharmacokinetic-Pharmacodynamic Relationships of H1-Antihistamines

Y. Horsmans, J. Desager, 1995, Clinical pharmacokinetics.

Embryotoxicity of human sera from patients treated with isotretinoin.

J. Desager, J. Picard, P. Therasse, 1993, Toxicology in vitro : an international journal published in association with BIBRA.

Dietary oligofructose lowers triglycerides, phospholipids and cholesterol in serum and very low density lipoproteins of rats

M. Roberfroid, N. Delzenne, J. Desager, 1995, Lipids.

Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6 beta-hydroxycortisol in 102 healthy subjects on rifampicin.

Y. Horsmans, J. Desager, C. Harvengt, 1992, Pharmacology & toxicology.

Alfentanil-Induced Miosis as a Surrogate Measure of Alfentanil Pharmacokinetics in Patients with Mild and Moderate Liver Cirrhosis

Y. Horsmans, P. Wallemacq, J. Desager, 2007, Clinical pharmacokinetics.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

J. Gala, Y. Horsmans, J. Desager, 2003, British journal of clinical pharmacology.

The vitamin A fat-loading test in young normolipidemic subjects.

J. Desager, C. Vandenplas, C. Harvengt, 1993, Clinica chimica acta; international journal of clinical chemistry.

Uricosuric Effect of Fenofibrate in Healthy Volunteers

J. Desager, C. Harvengt, R. Hulhoven, 1980, Journal of clinical pharmacology.

Beta-blocking agents and plasma lipids: an update.

J. Desager, C. Harvengt, F. Heller, 1987, Advances in experimental medicine and biology.

Lecithin: Cholesterol Acyltransferase Activity in Familial Hypercholesterolemia Treated with Simvastatin and Simvastatin Plus Low‐Dose Colestipol

Y. Horsmans, J. Desager, C. Harvengt, 1991, Journal of clinical pharmacology.

Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin.

R. Fagard, J. Desager, H. Celis, 1995, Journal of human hypertension.

Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure.

J. Desager, C. Harvengt, R. Verberckmoes, 1982, Nephron.

A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.

C. Gerlinger, J. Endrikat, U. Gaspard, 2004, Contraception.

Lack of effect by nifedipine on hepatic mixed function oxidase in man

S. Pauwels, Y. Horsmans, J. Desager, 1991, Fundamental & clinical pharmacology.

Sympathetic nervous system response in acute cardiovascular toxicity induced by amitriptyline in conscious rabbits.

J. Desager, C. Harvengt, M. Bogaert, 1978, Toxicology and applied pharmacology.

Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress

I. Leclercq, Y. Horsmans, J. Desager, 1998, Clinical pharmacology and therapeutics.

Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation.

I. Leclercq, N. Delzenne, Y. Horsmans, 1998, Journal of hepatology.

Scoparone O-demethylase assay is not useful to differentiate the effects of model inducers of cytochrome P-450 in rabbit and guinea pig liver.

Y. Horsmans, J. Desager, C. Harvengt, 1993, Life sciences.

Effects of simvastatin and pravastatin on 6 beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A.

Y. Horsmans, J. Desager, C. Harvengt, 1993, Pharmacological research.

Watercress has no Importance for the elimination of ethanol by CYP2E1 inhibition.

Y. Horsmans, J. Desager, Jean-Luc Golnez, 2002, Pharmacology & toxicology.

Plasma lipid concentrations and lecithin:cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol.

J. Desager, C. Harvengt, F. Heller, 1981, Metabolism: clinical and experimental.

Efficacy of enoximone in the management of refractory low output states following cardiac surgery.

J. Desager, E. Installé, M. Gonzalez, 1988, British journal of clinical practice. Supplement.

Atorvastatin and Low-Density Lipoprotein Subfractions Profile in Mixed Hyperlipidaemia: A Contributory Effect of Reduced Hepatic Lipase Activity?

O. Descamps, J. Desager, F. Heller, 1999, Annals of clinical biochemistry.

Quantitative determination of low levels of daunomycin and daunomycinol in plasma by high-performance liquid chromatography.

J. Desager, R. Hulhoven, 1976, Journal of chromatography.

Oral Bioavailability of Nizatidine and Ranitidine Concurrently Administered with Antacid

J. Desager, C. Harvengt, 1989, The Journal of international medical research.

Effects of gemfibrozil on plasma lipoproteins, plasma activities of hepatic enzymes, and hemostatic variables in hypertriglyceridemic patients

O. Descamps, J. Desager, C. Harvengt, 1995 .

Single daily oral dose of gemfibrozil reduces postprandial hyperlipidemia in hyperlipidemic patients

O. Descamps, J. Desager, F. Heller, 1998 .

Absolute bioavailability of amiodarone in normal subjects

J. Desager, C. Harvengt, Y. Berger, 1985, Clinical pharmacology and therapeutics.

Relative acute cardiovascular toxicity induced by maprotiline, mianserin and nomifensine in conscious rabbits.

J. Desager, C. Harvengt, 1983, Journal of toxicology. Clinical toxicology.

Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.

J. Belaiche, E. Louis, Y. Horsmans, 2001, Scandinavian journal of gastroenterology.

Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days.

Y. Horsmans, J. Desager, C. Vandenplas, 1996, Atherosclerosis.

CYP 3A proteins are expressed in human neutrophils and lymphocytes but are not induced by rifampicin.

C. Sempoux, Y. Horsmans, P. Stärkel, 1999, Life sciences.

The urinary 6 beta-hydroxycortisol excretion in man on inducers and inhibitors of the hepatic mixed function oxidase.

J. Desager, C. Harvengt, E. Dumont, 1987, Pharmacology & therapeutics.

Clinical Pharmacokinetics of Ticlopidine

J. Desager, 1994, Clinical pharmacokinetics.

Reduced cardiac output and renal blood flow during amitriptyline intoxication in conscious rabbits.

J. Desager, C. Harvengt, J. P. Leonard, 1979, Toxicology and applied pharmacology.

Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers.

J. Desager, C. Harvengt, 1978, International journal of clinical pharmacology and biopharmacy.

Effects of gemfibrozil on the activities of plasma lipolytic enzymes in normolipidemic subjects.

Y. Horsmans, J. Desager, C. Harvengt, 1993, Clinica chimica acta; international journal of clinical chemistry.

Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites

K. Desante, R. Frye, J. Sauer, 2003, Clinical pharmacology and therapeutics.

Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy

Y. Horsmans, J. Desager, A. Geubel, 1997, Alimentary pharmacology & therapeutics.

Implication of fibrate therapy for homocysteine

F. Jamar, O. Devuyst, E. Goffin, 1999, The Lancet.

D-propoxyphene and norpropoxyphene kinetics after the oral administration of D-propoxyphene: a new approach to liver function?

Y. Horsmans, J. Desager, A. Geubel, 1994, Journal of hepatology.

Atorvastatin and the plasma activities of lipoprotein lipase, hepatic lipase and lecithin:cholesterol acyltransferase in patients with mixed hyperlipidemia

O. Descamps, J. Desager, F. Heller, 2000 .

Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s disease

O. Dewit, Y. Horsmans, J. Desager, 2002, Alimentary pharmacology & therapeutics.

Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors

Y. Horsmans, J. Desager, 1996, Clinical pharmacokinetics.

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

T. Berg, K. Steffy, S. Fletcher, 2005, Hepatology.

Use of An Internal Standard To Assay 6 Beta-hydroxycortisol in Urine

M. Sclavons, J. Desager, E. Dumont, 1984 .

Relationship between mephenytoin, phenytoin and tolbutamide hydroxylations in healthy African subjects.

Y. Horsmans, J. Desager, J. Kanyinda, 1996, Pharmacology & toxicology.

Influence of diet on liver volume and cytochrome P-450 (CYP) activities in human non-alcoholic fatty liver.

I. Leclercq, S. Pauwels, Y. Horsmans, 1996 .

Serum beta-carotene in anorexia nervosa patients: a case-control study.

F. Zech, J. Desager, C. Beguin, 2001, The International journal of eating disorders.

Hydroxy-Methylglutaryl–Coenzyme A Reductase Inhibition Promotes Endothelial Nitric Oxide Synthase Activation Through a Decrease in Caveolin Abundance

C. Dessy, J. Desager, J. Balligand, 2001, Circulation.

Sensitive assay for midazolam and its metabolite 1'-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography.

Y. Horsmans, J. Desager, S. Eeckhoudt, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Midazolam and cortisol metabolism before and after CYP3A induction in humans.

I. Leclercq, Y. Horsmans, J. Desager, 2001, International journal of clinical pharmacology and therapeutics.

Interaction between azathioprine and aminosalicylates: An in vivo study in patients with Crohn's disease

O. Dewit, Y. Horsmans, J. Desager, 2001 .

Influence of repeated administration of cimetidine on the pharmacokinetics and pharmacodynamics of adinazolam in healthy subjects

J. Desager, C. Harvengt, R. Hulhoven, 2004, European Journal of Clinical Pharmacology.

CYP3A4 activity in four different animal species liver microsomes using 7-benzyloxyquinoline and HPLC/spectrofluorometric determination.

Y. Horsmans, J. Desager, Narine Baririan, 2006, Journal of pharmaceutical and biomedical analysis.

The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin.

P. Rosenzweig, G. Bianchetti, J. Desager, 1993, International journal of clinical pharmacology, therapy, and toxicology.

Naproxen Plasma Levels in Volunteers After Single‐Dose Administration by Oral and Rectal Routes

J. Desager, C. Harvengt, M. Vanderbist, 1976, Journal of clinical pharmacology.

Prevalence of drug hydroxylator phenotypes in Belgium

J. Desager, C. Harvengt, Y. Nieuwenhuyze, 2004, European Journal of Clinical Pharmacology.

Ritodrine serum levels: influence of dose and route of administration.

K. Thomas, J. Desager, C. Harvengt, 1984, International journal of clinical pharmacology, therapy, and toxicology.

Estimation of chlorzoxazone hydroxylase activity in liver microsomes and of the plasma pharmacokinetics of chlorzoxazone by the same high-performance liquid chromatographic method.

I. Leclercq, Y. Horsmans, J. Desager, 1998, Journal of chromatography. A.

Total, free and HDL cholesterol determination in serum by GLC. A fast and accurate method

J. Desager, C. Harvengt, 1978 .

Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias.

J. Desager, C. Harvengt, F. Heller, 1980, Artery.

Effects of Long-Term Therapy with the Association of Nisoldipine and a Beta-Blocker on Exercise Tolerance and Coronary Hemodynamics in Patients with Stable Angina: A Comparison with Monotherapy

C. Hanet, M. Rousseau, H. Pouleur, 1987 .

Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase.

J. Balligand, C. Dessy, J. Desager, 1999, The Journal of clinical investigation.

Comparison of the Effect of Celiprolol and Nifedipine on Blood Pressure and Plasma Lipids

J. Staessen, A. Amery, L. Thijs, 1992, Journal of Cardiovascular Pharmacology.

An improved gas‐liquid chromatographic method for determining practolol in plasma and urine

J. Desager, C. Harvengt, 1975, The Journal of pharmacy and pharmacology.

Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers

M. Longueville, J. Desager, C. Harvengt, 1997, Clinical pharmacology and therapeutics.

Effects of Combined Bezafibrate‐Simvastatin Appraised in Healthy Subjects

Y. Horsmans, J. Desager, C. Harvengt, 1992, Journal of clinical pharmacology.

Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients

B. Walker, S. Akira, J. Kaldor, 2011 .

Fast determination of low-level cytochrome P-450 1A1 activity by high-performance liquid chromatography with fluorescence or visible absorbance detection.

I. Leclercq, Y. Horsmans, J. Desager, 1996, Journal of chromatography. B, Biomedical applications.

The metabolic fate of14C or35S labelled tiadenol in rabbit after i.v. and oral administration

M. Sclavons, J. Desager, C. Harvengt, 1986, European Journal of Drug Metabolism and Pharmacokinetics.

LACK OF CLINICALLY RELEVANT INTERACTION OF CETIRIZINE ON THEOPHYLLINE DISPOSITION IN HEALTHY SUBJECTS: A PLACEBO‐CONTROLLED STUDY

J. Desager, C. Harvengt, R. Hulhoven, 1995, American journal of therapeutics.

Changes in lipoprotein composition in women receiving two low-dose oral contraceptives containing ethinylestradiol and gonane progestins.

U. Gaspard, J. Desager, C. Harvengt, 1988, Contraception.

Effect of colestipol, a new bile acid sequestrant, on the absorption of phenprocoumon in man

J. Desager, C. Harvengt, 1973, European Journal of Clinical Pharmacology.

Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects.

J. Desager, C. Harvengt, R. Hulhoven, 1985, International journal of clinical pharmacology, therapy, and toxicology.

Metabolic Interaction of Cimetidine With Alprazolam and Triazolam After Repeated Doses

J. Desager, C. Harvengt, E. Dumont, 1984 .

Amitriptyline binding to specific alpha-adrenergic receptors in vitro.

J. Desager, C. Harvengt, J. P. Leonard, 1980, Life sciences.

Lack of interaction between zolpidem and H2 antagonists, cimetidine and ranitidine.

P. Hermann, J. Desager, C. Harvengt, 1988, International journal of clinical pharmacology research.

4P-1061 Altered blood pressure and heart rate variability in hypercholesterolemic apoE-/-mice is corrected by rosuvastatin independently of its plasma lipid lowering activity

J. Balligand, C. Dessy, M. Pelat, 2003 .

Influence of the Hemodialysis on the Half‐Life of Practolol in Patients with Severe Renal Failure

J. Desager, C. Harvengt, R. Verberckmoes, 1975, Journal of clinical pharmacology.

Phenytoin hydroxylation in a healthy Caucasian population: bimodal distribution of hydroxyphenytoin urinary excretion.

Y. Horsmans, J. Desager, A. Bouckaert, 1997, Pharmacology & toxicology.

Life Threatening Hyperkalemia Associated with Clofibrate-Induced Myopathy in a CAPD Patient

J. Desager, F. Belpaire, S. Ringoir, 1983 .

Alfentanil‐Induced Miosis Clearance as a Liver CYP3A4 and 3A5 Activity Measure in Healthy Volunteers: Improvement of Experimental Conditions

Y. Horsmans, P. Wallemacq, J. Desager, 2005, Journal of clinical pharmacology.

Pharmacokinetics and Disposition of Nifedipine and Acebutolol As a Fixed Combination Or Given Separately After Single and Repeated Dose in Healthy-subjects

M. Sclavons, J. Desager, C. Harvengt, 1986 .

Hydroxy-Methylglutaryl–Coenzyme A Reductase Inhibition Promotes Endothelial Nitric Oxide Synthase Activation Through a Decrease in Caveolin Abundance

C. Dessy, J. Desager, J. Balligand, 2001, Circulation.

Lack of pharmacokinetic interaction of colestipol and fenofibrate in volunteers

J. Desager, C. Harvengt, 1980, European Journal of Clinical Pharmacology.

Gas--liquid chromatographic determination of procetofenic acid in human plasma and urine.

J. Desager, 1978, Journal of chromatography.

A pharmacokinetic evaluation of the second‐generation H1‐receptor antagonist cetirizine in very young children

Y. Horsmans, J. Desager, C. Harvengt, 1993, Clinical pharmacology and therapeutics.

14C-Propoxyphene demethylation in the rat. An example of differences between liver and intestinal drug-presystemic metabolism.

A. Saliez, S. Pauwels, Y. Horsmans, 1997, Drug metabolism and disposition: the biological fate of chemicals.

An improvement of Barter's method for assaying plasma cholesterol ester transfer activity: experimental and clinical applications.

J. Desager, C. Harvengt, F. Heller, 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors

Y. Horsmans, J. Desager, 1996, Clinical pharmacokinetics.

Fast separation of the three main plasma lipoprotein classes by ultracentrifugation using vertical rotor and multiple discontinuous density gradient.

M. Sclavons, J. Desager, C. Harvengt, 1985, Clinica chimica acta; international journal of clinical chemistry.

Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?

Y. Horsmans, J. Desager, C. Harvengt, 1991, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.

Y. Horsmans, J. Desager, C. Harvengt, 1989, International journal of clinical pharmacology, therapy, and toxicology.

Hypotriglyceridemic action of omega-3 fatty acids in healthy subjects does not occur by enhanced lipoprotein lipase and hepatic lipase activities.

J. Dricot, J. Desager, C. Harvengt, 1989, Research communications in chemical pathology and pharmacology.

Absolute bioavailability of mianserin tablets and solution in healthy humans

M. Sclavons, J. Desager, C. Harvengt, 1985, European Journal of Drug Metabolism and Pharmacokinetics.

Plasma levels and biotransformation of infused daunorubicin and daunorubicin-DNA complex in rabbits: a preliminary report.

J. Desager, C. Harvengt, R. Hulhoven, 1977, European journal of cancer.